HEPATIC STEATOSIS AS DIABETES TYPE 2 PREDICTOR

被引:9
|
作者
Loureiro, Carolina [1 ]
Martinez-Aguayo, Alejandro [1 ]
Campino, Carmen [2 ]
Carvajal, Cristian [2 ]
Fardella, Carlos [2 ]
Garcia, Hernan [1 ]
机构
[1] Pontificia Univ Catolica Chile, Div Pediat, Unidad Endocrinol Pediat, Santiago 8330074, Chile
[2] Pontificia Univ Catolica Chile, Dept Endocrinol, Santiago 8330074, Chile
关键词
Non alcoholic fatty liver disease (NAFLD); Steatohepatitis; Alanine aminotransferase; Insulin resistance; Type; 2; diabetes; FATTY LIVER-DISEASE; INSULIN-RESISTANCE; ALANINE AMINOTRANSFERASE; OBESE ADOLESCENTS; ADIPOSE-TISSUE; CHILDREN; ADIPONECTIN; PREVALENCE; INTERLEUKIN-6; OVERWEIGHT;
D O I
10.3305/nh.2014.29.2.7098
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Non alcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance (IR) and increased type 2 diabetes (T2D). Alanine aminotransferase (ALT) is recognized as biochemical marker of NAFLD, currently used as screening for this disease. Objective: To estimate the associations between (ALT) with anthropometric variables, insulin resistance and inflamatory markers in pediatric population. Patients and Method: we studied 348 subjects (52.7% females), aged between 4.9 and 15.6 years. Blood samples for measuring: AST, ALT, glycaemia, insulin, lipid profile, hsCRP TNF-alpha, IL-6 and adiponectin. We calculate HOMA-IR, QUICKI y el HOMA-beta. The results are expressed are expressed as median interquartile range. Variables were log10 transformed before Pearson correlations analyze. Results: Serum ALT levels were positively associated with BMI-SDS (r = 0.335), waist/height ratio (r = 0.358), insulin (r = 0.33), HOMA-IR (r = 0.33), HOMA-beta (r = 0.26), TG/HDL-c (r = 0.2), hsCRP (r = 0.3); and a negative association with QUICKI (r = -0.25) and adiponectin (r = -0.113). Non-association with ALT, glycaemia, TNF-a and IL-6 was found. Conclusion: Our study demonstrated that ALT, but not AST, was significantly correlated with of insulin resistance and inflamatory markers, all of them recognized as risk parameters of pre diabetes stage. ALT should be part of the evaluation of all obesity children, mainly those with other cardiometabolic risk factors, since it could predict later development of T2DM. Further imaging studies are necessary to confirm fatty liver disease in this population.
引用
收藏
页码:350 / 358
页数:9
相关论文
共 50 条
  • [11] Effect of insulin resistance on hepatic function in type 2 diabetes
    El Oudi, M.
    Ouertani, H.
    Aouni, Z.
    Mazigh, C.
    Zidi, B.
    Machghoul, S.
    IMMUNO-ANALYSE & BIOLOGIE SPECIALISEE, 2009, 24 (03): : 121 - 125
  • [12] Insulin resistance and hepatic steatosis in type 1 diabetes mellitus and their association with diabetic chronic complications
    Popa, Simona G.
    Simion, Ana M.
    Soare, Mariana
    Arcomita, Doina
    MINERVA ENDOCRINOLOGY, 2023, 48 (01): : 27 - 34
  • [13] Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes
    Choe, Eun Yeong
    Lee, Yong-ho
    Choi, Young Ju
    Huh, Byung Wook
    Lee, Byung-Wan
    Kim, Soo-Kyung
    Kang, Eun Seok
    Cha, Bong-Soo
    Lee, Eun Jig
    Huh, Kap Bum
    Younossi, Zobair M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (05) : 1082 - 1091
  • [14] Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes
    Banitalebi, Ebrahim
    Faramarzi, Mohammad
    Nasiri, Samira
    Mardaniyan, Majid
    Rabiee, Vahid
    CLINICAL AND MOLECULAR HEPATOLOGY, 2019, 25 (03) : 294 - 304
  • [15] Glycogenic hepatopathy associated with hepatic steatosis in type 1 diabetes
    Teasdale, Stephanie
    Dong, Xin
    Griffin, Alison
    Clark, Paul James
    Nisbet, Janelle
    Morton, Adam
    Phillips, Liza
    Sullivan, Mitchell Anthony
    Galloway, Graham
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2024, 38 (11)
  • [16] Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes
    Hayashi, Yasuhiro
    Suemitsu, Erina
    Kajimoto, Kazuaki
    Sato, Yusuke
    Akhter, Afsana
    Sakurai, Yu
    Hatakeyama, Hiroto
    Hyodo, Mamoru
    Kaji, Noritada
    Baba, Yoshinobu
    Harashima, Hideyoshi
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2014, 3 : e154
  • [17] Hepatic steatosis and Type 2 diabetes: current and future treatment considerations
    Richard, John
    Lingvay, Ildiko
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2011, 9 (03) : 321 - 328
  • [18] Effect of Insulin Versus Triple Oral Therapy on the Progression of Hepatic Steatosis in Type 2 Diabetes
    Lingvay, Ildiko
    Roe, Erin D.
    Duong, Jonathan
    Leonard, David
    Szczepaniak, Lidia S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (07) : 1059 - 1063
  • [19] Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)
    Lavynenko, Olga
    Abdul-Ghani, Muhammad
    Alatrach, Mariam
    Puckett, Curtiss
    Adams, John
    Abdelgani, Siham
    Alkhouri, Naim
    Triplitt, Curtis
    Clarke, Geoffrey D.
    Vasquez, Juan A.
    Li, Jinqi
    Cersosimo, Eugenio
    Gastaldelli, Amalia
    DeFronzo, Ralph A.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 899 - 907
  • [20] Association of Diabetic Retinopathy with Midlife Hepatic Steatosis Diagnosed by Elastography and Hepatic Steatosis Index in Type 2 Diabetes in an Indian Population
    Mandal, Mily
    Ghosh, Sambuddha
    Roy, Satarupa
    Mandal, Sayani
    Dasgupta, Anindya
    METABOLIC SYNDROME AND RELATED DISORDERS, 2024, 22 (03) : 214 - 221